The glial cell modulator and phosphodiesterase inhibitor, AV411 (ibudilast), attenuates prime- and stress-induced methamphetamine relapse.
Stress and renewed contact with drug (a "slip") have been linked to persisting relapse of methamphetamine abuse. Human brain microglial activation has been linked with methamphetamine abuse, and inhibitors of glial cell activation, certain phosphodiesterase (PDE) inhibitors, and glial cell derived neurotrophic factor (GDNF) have been reported to modulate drug abuse effects. Our objective was to determine whether the glial cell attenuator, 3-isobutyryl-2-isopropylpyrazolo-[1,5-a]pyridine (AV411, ibudilast), a non-selective PDE inhibitor and promoter of GDNF, could reduce stress- and methamphetamine prime-induced reinstatement of methamphetamine-seeking behavior. Male Long-Evans hooded rats were trained to lever press reinforced with 0.1 mg/kg i.v. methamphetamine infusion according to fixed-ratio 1 (FR1) reinforcement schedules during daily, 2-hour experimental sessions. After performance had stabilized, lever pressing was extinguished for 12 consecutive sessions and doses of 0 (vehicle), 2.5 and 7.5 mg/kg AV411 were then administered intraperitoneally b.i.d. on the last 2 days of extinction and then once on the testday to separate groups of 12 rats. During testing, the rats were given 15 min of intermittent footshock or a 1 mg/kg i.p. methamphetamine prime followed by a 2-hour reinstatement test session. AV411 significantly reduced response levels of footshock-induced (2.5 and 7.5 mg/kg) and prime-induced (7.5 mg/kg) reinstatement of extinguished methamphetamine-maintained responding. AV411 has properties consistent with the ability to attenuate relapse precipitated by stress and methamphetamine "slips" during abstinence. These results thus reinforce interest in atypical neurobiological mechanisms which could be exploited for developing novel medications for treating drug abuse disorders.
Beardsley
Patrick M
PM
Department of Pharmacology & Toxicology, Virginia Commonwealth University, Richmond, VA 3298-0613, USA. pbeardsl@vcu.edu
Shelton
Keith L
KL
Hendrick
Elizabeth
E
Johnson
Kirk W
KW
D019969:Amphetamine-Related Disorders / Q000188:drug therapy* / Q000503:physiopathology; D000818:Animals; D004305:Dose-Response Relationship, Drug; D007274:Injections, Intraperitoneal; D008297:Male; D008694:Methamphetamine / Q000378:metabolism*; D009457:Neuroglia / Q000187:drug effects* / Q000378:metabolism; D010726:Phosphodiesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D011725:Pyridines / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D051381:Rats; D020318:Rats, Long-Evans; D055502:Secondary Prevention; D013315:Stress, Psychological / Q000503:physiopathology*; D013997:Time Factors; D007212:Indolizines; D011720:Pyrazoles
D008694:Methamphetamine; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; C038366:ibudilast; D007212:Indolizines; D011720:Pyrazoles
Expert Opin Investig Drugs. 2007 Jul;16(7):935-50
17594181
Neuron. 2000 Apr;26(1):247-57
10798408
Psychopharmacology (Berl). 2008 Feb;196(2):233-41
17909751
Eur J Pharmacol. 2006 May 24;538(1-3):39-42
16674936
Behav Brain Res. 2001 Jan 8;118(1):85-93
11163637
FASEB J. 2007 Jul;21(9):1994-2004
17356005
Synapse. 2000 Mar 15;35(4):243-9
10657033
Glia. 2003 Sep;43(3):218-03
12898701
Nature. 1994 Jun 30;369(6483):744-7
7911978
Proc Natl Acad Sci U S A. 2006 May 30;103(22):8523-7
16717181
J Pharmacol Exp Ther. 2004 Oct;311(1):1-7
15163680
Trends Neurosci. 2005 Dec;28(12):661-9
16246435
Brain Res. 1998 Dec 14;814(1-2):120-6
9838075
Biol Psychiatry. 2007 Apr 1;61(7):890-901
17046726
Brain Behav Immun. 2009 Feb;23(2):240-50
18938237
J Neurosci Res. 2004 Oct 15;78(2):250-8
15378610
Neuropsychopharmacology. 2004 Jul;29(7):1270-81
15039771
Nat Neurosci. 1998 Dec;1(8):683-92
10196584
Eur J Neurosci. 2004 May;19(9):2561-8
15128409
Jpn J Pharmacol. 2000 Jun;83(2):113-8
10928323
J Neurosci. 1996 Dec 15;16(24):8132-9
8987838
Psychopharmacology (Berl). 2007 Feb;190(2):171-80
17119930
Ann N Y Acad Sci. 2004 Oct;1025:504-7
15542755
Glia. 2001 Oct;36(1):11-21
11571780
Pharmacol Biochem Behav. 2008 Sep;90(3):434-40
18456312
Behav Brain Res. 2006 Oct 2;173(1):39-46
16857277
Br J Clin Pharmacol. 2008 Dec;66(6):792-801
19032723
Neuron Glia Biol. 2006 Nov;2(4):279-91
18176632
Brain Res. 1999 Aug 7;837(1-2):203-12
10434004
Neuroscience. 2003;122(2):499-513
14614914
Eur J Pharmacol. 2002 Jul 19;448(2-3):165-8
12144937
Neuropharmacology. 2004 Mar;46(3):404-11
14975696
Ann N Y Acad Sci. 2000 Sep;914:127-36
11085315
Eur J Pharmacol. 2007 Jun 22;565(1-3):113-8
17408614
Br J Pharmacol. 2001 Mar;132(5):1111-7
11226142
Naunyn Schmiedebergs Arch Pharmacol. 2003 May;367(5):490-9
12684743
Eur J Pharmacol. 2007 Nov 21;574(1):39-48
17869241
Brain Res. 1999 May 8;827(1-2):104-12
10320698
ScientificWorldJournal. 2007 Nov 02;7:98-111
17982582
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Dec 30;30(8):1381-93
16839653
Neurosci Lett. 2004 Sep 9;367(3):349-54
15337264
Expert Opin Pharmacother. 2009 Dec;10(17):2897-904
19929708
Neuropsychopharmacology. 1995 Aug;13(1):33-9
8526969
Neuroscience. 2004;124(2):377-86
14980387
Eur J Pharmacol. 1996 Sep 26;312(2):163-70
8894591
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1964-9
11172059
Brain Behav Immun. 2007 Feb;21(2):131-46
17175134
Neuropharmacology. 2004 Apr;46(5):734-42
14996551
Biol Psychiatry. 2004 Jun 1;55(11):1082-9
15158427
Arch Med Res. 2006 Jan;37(1):11-8
16314180
Exp Neurol. 2004 May;187(1):47-57
15081587
J Neurosci. 2007 Aug 15;27(33):8816-25
17699663
Neurosci Res. 2001 Mar;39(3):281-6
11248367
Nature. 1998 Jan 15;391(6664):281-5
9440691
Neuropsychopharmacology. 2006 Nov;31(11):2476-88
16407899
Behav Brain Res. 2007 Apr 16;179(1):167-71
17331595
Ann N Y Acad Sci. 2006 Aug;1074:272-81
17105923
Biol Psychiatry. 2007 Sep 15;62(6):658-68
17217924
Glia. 2004 Aug 15;47(3):209-16
15252809
Neuropsychopharmacology. 2004 Aug;29(8):1470-8
15085091
Neuropharmacology. 2009 Apr;56(5):856-65
19371575